ITCAN Launches Public Awareness Campaign for Zonnic Nicotine Pouches

Business by 2FIRSTS.ai
Apr.16.2024
ITCAN Launches Public Awareness Campaign for Zonnic Nicotine Pouches
ITCAN launches public campaign to educate about Zonnic nicotine pouches, aiming to dispel misunderstandings and promote smoking reduction in Canada.

According to a statement released by Imperial Tobacco Canada (ITCAN), the company has launched a public awareness campaign to broaden the public's knowledge of Zonnic nicotine pouches. The company stated that the goal of the campaign is to dispel misconceptions and provide accurate scientific information about nicotine replacement therapy (NRT) and how Zonnic can reduce tobacco use in Canada.

 

ITCAN President and CEO Frank Silva stated in a declaration, "Our new Zonnic advertising campaign affirms the statements about Zonnic nicotine pouches and reflects our dedication to reducing tobacco harm and commitment to helping Canada decrease smoking rates." The company pointed out that since Zonnic was launched in October last year, anti-tobacco lobbying groups and the federal health department have been making accusations and incorrect descriptions about it.

 

Silva stated: "Our goal is very clear; we want to help those who want to quit smoking, as long as they are willing to quit."

 

According to him, this initiative begins with the release of innovative and unique alternatives, ensuring that these products are readily available to adults while also preventing minors from accessing any form of nicotine products, including NRTs. Our stance includes the belief that any form of NRT should require age verification before purchase and be stored in a way that minors cannot access them in retail locations.

 

Silva said, "We have tried to meet with Minister Herland, our doors are always open to him, but he has not responded to our calls. We are very willing to have a fair, fact-based discussion to keep NRT available to adult smokers and prevent nicotine products from falling into the hands of teenagers. By working together, we can achieve the goals of your department, goals that we share."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
EVO NXT: two days, four zones, countless opportunities
EVO NXT: two days, four zones, countless opportunities
Mar.30
UK Vape Waste Falls 23% From 2024, but Recycling Group Says Fire Risks Remain High
UK Vape Waste Falls 23% From 2024, but Recycling Group Says Fire Risks Remain High
New research from UK recycling campaign group Material Focus says more than 6.3 million vapes and pods are still thrown away each week in the UK. The figure is down 23% from 8.2 million in 2024, which the group said suggests the June 2025 single-use vape ban has helped reduce waste, but it warned that the current level still represents a major waste of valuable materials and a significant fire risk.
Mar.27 by 2FIRSTS.ai
Canada’s Federal Vape Flavor Restrictions Remain Unclear Five Years After Announcement
Canada’s Federal Vape Flavor Restrictions Remain Unclear Five Years After Announcement
Five years after Canada’s federal government announced plans to restrict vaping flavors nationwide, Health Minister Marjorie Michel has not said when or whether the measure will still proceed. In 2021, Health Canada said it planned to limit vaping flavors nationwide to mint, menthol and tobacco, citing evidence that fruity and sweet flavors appeal to youth.
May.11 by 2FIRSTS.ai
2Firsts Hosts UK Vape Duty Stamp Compliance Exchange in Shenzhen
2Firsts Hosts UK Vape Duty Stamp Compliance Exchange in Shenzhen
2Firsts held a UK vape duty stamp compliance exchange in Shenzhen on May 14, bringing together representatives from nearly 20 companies. The session addressed Vaping Products Duty, duty stamp applications, UK agency qualifications and warehousing, while introducing 2Firsts Compliance Solutions’ UK service.
Events
May.17
FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA’s Center for Tobacco Products and NIH’s National Institute on Drug Abuse announced that new Wave 8 restricted-use data files from the PATH Study are now available. The files contain data collected between January 2024 and December 2024, including questionnaire data, location characteristics data, and state identifier data.
Apr.17 by 2FIRSTS.ai